Abstract: Anti-vascular endothelial growth factor (VEGF) fusion protein consisting of VEGF receptor and Fc segment of human IgG, which can be competitive with VEGF receptor in combination with VEGF, thereby VEGF receptor will be prevented from being activated. As the binding capacity of anti-VEGF fusion protein to VEGF is much higher than that of monoclonal anti-VEGF drugs, the high-affinity anti-VEGF drugs has been widely applied in the treatment of diseases abnormally caused by generation, releasing and activation of VEGF. At present, it is mainly used to reduce VEGF production to subside or prevent neovascularization and treatment of macular edema associated with various vascular diseases. Since anti-VEGF fusion protein appeared later than monoclonal drugs, most studies have found that anti-VEGF fusion protein can be used to treat diseases poorly treated by monoclonal drugs. At the same time, it has also been reported that the therapeutic effect of anti-VEGF drugs replacement is better than that of single drug. Anti-tumor therapy is also a potential field for anti-VEGF fusion protein drugs. According to the research on the expression of anti-VEGF fusion protein drugs acting factor and related factors of myopia formation, they may have inhibitory effect on myopia formation. (Int Rev Ophthalmol, 2020, 44：126-132)